SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

AUGMENTIN TABLETS

of the mixture

Registration number

AUGMENTIN 156.25 MG TABLETS * AUGMENTIN 250 MG TABLETS * AUGMENTIN 500 MG **Synonyms**

TABLETS * AUGMENTIN 187.5 MG TABLETS * AUGMENTIN 375 MG TABLETS * AUGMENTIN 625 MG TABLETS * AUGMENTAN TABLETS * AUGMENTIN 2:1 TABLETS * AUGMENTIN 4:1 TABLETS * CLAVULIN 250 TABLETS * CLAVULIN 500F TABLETS * AMOCLAV 375 MG

TABLETS * AMOCLAV 625 MG TABLETS * CLAMOXYL TABLETS 250 MG * SPEKTRAMOX 375 MG FINAL TABLETS * NDC NO. 0029-6075-27 * NDC NO. 0029-6075-31 * NDC NO.

0029-6080-12 * NDC NO. 0029-6080-31 * AMOXICILLIN TRIHYDRATE AND POTASSIUM

CLAVULANATE, FORMULATED PRODUCT

Issue date 11-July-2014

Version number

Revision date 11-July-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

No other uses are advised. Uses advised against

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 +1 703 527 3887 International toll call:

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies.

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information None.

2.3. Other hazards Assume that this product is capable of sustaining combustion.

Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Material name: AUGMENTIN TABLETS

General information

Chemical name % CAS-No. / EC No. REACH Registration No. INDEX No. Notes

AMOXICILLIN TRIHYDRATE 35 - < 60 61336-70-7 -

2480038

Classification: DSD: R42/43

CLP: Skin Sens. 1;H317, Resp. Sens. 1;H334

POTASSIUM CLAVULANATE 6 - < 24 61177-45-5 -

262-640-9

Classification: DSD: F;R11-R17

CLP: Flam. Sol. 1;H228, Self-heat. 1;H251

MICROCRYSTALLINE CELLULOSE 5 - < 10 9004-34-6 - -

232-674-9

Classification: DSD: -

CLP: -

MAGNESIUM STEARATE 1 - < 3 557-04-0 - -

209-150-3

Classification: DSD: -

CLP: -

Silicon dioxide 1 - < 3 7631-86-9 - -

231-545-4

Classification: DSD: -

CLP: -

Other components below reportable levels 30 - < 40

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information Wash contaminated clothing before reuse.

4.1. Description of first aid measures

Inhalation If dust from the material is inhaled, remove the affected person immediately to fresh air. Oxygen or

artificial respiration if needed. Do not use mouth-to-mouth method if victim inhaled the substance. Induce artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper respiratory medical device. If experiencing respiratory symptoms: Call a POISON CENTRE

or doctor/physician.

Skin contact Remove contaminated clothing immediately and wash skin with soap and water. In case of

eczema or other skin disorders: Seek medical attention and take along these instructions. For

minor skin contact, avoid spreading material on unaffected skin.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. Get medical attention if symptoms occur.

4.2. Most important symptoms and effects, both acute and

delayed

Possible effects of overexposure in the workplace include: symptoms of hypersensitivity (such as

skin rash, hives, itching, and difficulty breathing), nausea, vomiting, diarrhoea.

2928 Version No.: 20 Revision date: 11-July-2014 Issue date: 11-July-2014

4.3. Indication of any immediate medical attention and special treatment needed

Symptoms may be delayed. Medical treatment in cases of overexposure should be treated as an overdose of penicillin antibiotic. In allergic individuals, exposure to this material may require treatment for initial or delayed allergic symptoms and signs. This may include immediate and/or delayed treatment of anaphylactic reactions. Treat according to locally accepted protocols. For additional guidance, refer to the local poison control information centre. This material may cause or aggravate allergy to penicillin antibiotics. The need for pre-placement and periodic health surveillance must be determined by risk assessment. Following assessment, if the risk of exposure is considered significant then exposed individuals should receive health surveillance focused on detecting respiratory symptoms and including respiratory function testing.

In the event of overexposure, individuals should receive post exposure health surveillance focused on detecting respiratory conditions and other allergy symptoms. Ocular symptoms may be indicative of allergic reaction. Pulmonary symptoms may indicate allergic reaction or asthma.

SECTION 5: Firefighting measures

General fire hazards Assume that this product is capable of sustaining combustion.

None known.

5.1. Extinguishing media

Suitable extinguishing

media

Unsuitable extinguishing media

5.2. Special hazards arising from the substance or mixture

5.3. Advice for firefighters

Special protective equipment for firefighters

Special fire fighting procedures

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Move containers from fire area if you can do so without risk.

Foam. Dry chemical powder. Carbon dioxide (CO2). Water.

During fire, gases hazardous to health may be formed.

Use standard firefighting procedures and consider the hazards of other involved materials. Specific methods

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions

6.3. Methods and material for

containment and cleaning up

6.4. Reference to other sections

Avoid discharge into drains, water courses or onto the ground.

Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water.

For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene

7.2. Conditions for safe storage, including any incompatibilities

Store in original tightly closed container. Store in a well-ventilated place. Store away from incompatible materials (see Section 10 of the SDS).

Medicinal Product 7.3. Specific end use(s)

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

Material name: AUGMENTIN TABLETS

| GSK Components | Туре | Value | Note |
|---|-------------|------------|---------------------------|
| AMOXICILLIN TRIHYDRATE (CAS 61336-70-7) | 15 MIN STEL | 100 mcg/m3 | |
| , | OHC | 3 | SKIN SENSITISER |
| | | 3 | RESPIRATORY SENSITISER |

2928 Version No.: 20 Revision date: 11-July-2014 Issue date: 11-July-2014

SDS LIK

| GSK | | | |
|--|---|------------------------------|------------------|
| Components | Туре | Value | Note |
| MAGNESIUM STEARATE | OHC | 1 | |
| (CAS 557-04-0) MICROCRYSTALLINE CELLULOSE (CAS | OHC | 1 | |
| 9004-34-6) POTASSIUM CLAVULANATE (CAS 61177-45-5) | 8 HR TWA | 5000 mcg/m3 | |
| , | OHC | 1 | |
| Silicon dioxide (CAS 7631-86-9) | OHC | 1 | |
| SODIUM STARCH GLYCOLATE (CAS 9063-38-1) | OHC | 1 | |
| UK. EH40 Workplace Expos | ure Limits (WELs) | | |
| Components | Type | Value | Form |
| MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6) | STEL | 20 mg/m3 | Inhalable dust. |
| , | TWA | 4 mg/m3 | Respirable dust. |
| | | 10 mg/m3 | Inhalable dust. |
| Silicon dioxide (CAS 7631-86-9) | TWA | 6 mg/m3 | Inhalable dust. |
| , | | 2.4 mg/m3 | Respirable dust. |
| ological limit values | No biological exposure limits noted for the | e ingredient(s). | |
| commended monitoring ocedures | Follow standard monitoring procedures. | | |
| rived no-effect level (DNEL) | Not available. | | |
| edicted no effect ncentrations (PNECs) | Not available. | | |
| 2. Exposure controls | | | |
| propriate engineering ntrols | Not available. | | |
| lividual protection measures, | such as personal protective equipment | | |
| General information | Personal protection equipment should be discussion with the supplier of the person personal protective equipment (PPE) is upper solution. | nal protective equipment. Fo | |
| Eye/face protection | Not normally needed. If contact is likely, safety glasses with side shields are recommended. (eg. EN 166) | | |
| | | | |

In

Skin protection

- Hand protection Not normally needed. For prolonged or repeated skin contact use suitable protective gloves. Select

suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min

permeation time).

- Other Not normally needed. Wear suitable protective clothing as protection against splashing or

contamination. (EN 14605 for splashes, EN ISO 13982 for dust)

No personal respiratory protective equipment normally required. When workers are facing **Respiratory protection**

> concentrations above the exposure limit they must use appropriate certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic,

inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387).

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures An occupational/industrial hygiene monitoring method has been developed for this material. For

advice on suitable monitoring methods, seek guidance from a qualified environment, health and

safety professional.

Environmental exposure controls

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Material name: AUGMENTIN TABLETS 2928 Version No.: 20 Revision date: 11-July-2014 Issue date: 11-July-2014 **Appearance**

Solid. Physical state Tablet. **Form**

Colour Not available. Odour Not available. Not available. **Odour threshold** Not available. Melting point/freezing point Not available. Not available. Initial boiling point and boiling

range

Not available. Flash point Not available. **Evaporation rate** Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

(%)

Not available.

Not available. Vapour pressure Vapour density Not available. Relative density Not available.

Solubility(ies)

Not available. Solubility (water) Not available. Solubility (other) Not available. Partition coefficient

(n-octanol/water)

Not available. Auto-ignition temperature **Decomposition temperature** Not available. Not available. **Viscosity Explosive properties** Not available. Not available. **Oxidizing properties**

9.2. Other information No relevant additional information available.

SECTION 10: Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport. 10.1. Reactivity

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Contact with incompatible materials. 10.4. Conditions to avoid Strong oxidising agents. Fluorine. 10.5. Incompatible materials

10.6. Hazardous

Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

decomposition products

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Ingestion Expected to be a low ingestion hazard. Health injuries are not known or expected under normal

Inhalation Health injuries are not known or expected under normal use.

Skin contact May cause an allergic skin reaction. Health injuries are not known or expected under normal use.

Eye contact Direct contact with eyes may cause temporary irritation.

Symptoms Possible effects of overexposure in the workplace include: symptoms of hypersensitivity (such as

skin rash, hives, itching, and difficulty breathing), nausea, vomiting, diarrhoea.

11.1. Information on toxicological effects

Material name: AUGMENTIN TABLETS

Acute toxicity Health injuries are not known or expected under normal use.

2928 Version No.: 20 Revision date: 11-July-2014 Issue date: 11-July-2014

Test results Components **Species**

AMOXICILLIN TRIHYDRATE (CAS 61336-70-7)

Acute

Oral

LD50 Rat > 2000 mg/kg

MAGNESIUM STEARATE (CAS 557-04-0)

Acute

Oral

LD50 Rat > 2000 mg/kg

MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)

Acute Dermal

LD50 Rabbit > 2000 mg/kg

Oral

LD50 Rat > 2000 mg/kg

POTASSIUM CLAVULANATE (CAS 61177-45-5)

Acute Oral

LD Rat > 5000 mg/kg

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Corrosivity

AMOXICILLIN TRIHYDRATE Acute dermal irritation

> Result: negative Species: Rabbit **OECD 404** Result: Non-irritant

POTASSIUM CLAVULANATE

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE

Serious eye damage/eye irritation

Direct contact with eyes may cause temporary irritation. Health injuries are not known or expected

under normal use.

Eye

POTASSIUM CLAVULANATE **OECD 405**

Result: Non-Irritating

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days AMOXICILLIN TRIHYDRATE Result: Minimal irritant Species: Rabbit

Recovery Period: 2 days

Respiratory sensitisation May cause allergy or asthma symptoms or breathing difficulties if inhaled. Health injuries are not

known or expected under normal use.

Skin sensitisation May cause an allergic skin reaction. Health injuries are not known or expected under normal use.

Sensitisation

AMOXICILLIN TRIHYDRATE Epidemiology

Result: positive Species: Human

POTASSIUM CLAVULANATE Maximisation assay (Magnusson and Kligman)

> Result: negative Species: Guinea pig

SAR

Result: No structural alerts identified.

No data available to indicate product or any components present at greater than 0.1% are Germ cell mutagenicity

mutagenic or genotoxic.

Mutagenicity

POTASSIUM CLAVULANATE Ames

Result: negative AMOXICILLIN TRIHYDRATE GreenScreen Result: negative

Mouse Lymphoma Cell Assay

Result: negative

POTASSIUM CLAVULANATE Mouse Lymphoma Cell Assay

Result: negative

Material name: AUGMENTIN TABLETS

SDS LIK 6 / 10 2928 Version No.: 20 Revision date: 11-July-2014 Issue date: 11-July-2014

Mutagenicity

POTASSIUM CLAVULANATE SAR

Result: No structural alerts identified.

Health injuries are not known or expected under normal use. Carcinogenicity

POTASSIUM CLAVULANATE SAR

Result: No structual alerts identified.

IARC Monographs. Overall Evaluation of Carcinogenicity

SILICON DIOXIDE (CAS 7631-86-9) 3 Not classifiable as to carcinogenicity to humans.

Reproductive toxicity Health injuries are not known or expected under normal use.

Reproductivity

POTASSIUM CLAVULANATE Fertility (IV)

Result: Reproductive and developmental NOAEL 75

mg/kg/day Species: Rat

AMOXICILLIN TRIHYDRATE Fertility/foetal development, Rat and Mouse

Result: No effect

POTASSIUM CLAVULANATE Reproduction/Fertility Study (IV)

Result: Reproductive performance NOAEL 150 mg/kg/day

Species: Rabbit

Reproduction/Fertility Study (IV)

Result: Teratogenic and embryotoxic NOAEL 150 mg/kg/day

Species: Rat

Specific target organ toxicity -

single exposure

None known.

Specific target organ toxicity -

repeated exposure

None known.

Not likely, due to the form of the product. **Aspiration hazard**

Mixture versus substance

information

No information available.

Other information Caution - Pharmaceutical agent.

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

| Components | | Species | Test results |
|----------------------|-------------------|--|-----------------------------------|
| AMOXICILLIN TRIHYDRA | TE (CAS 61336-70- | -7) | |
| Aquatic | | | |
| Acute | | | |
| Algae | EC50 | Green algae (Selenastrum capricornutum) | 630 mg/l, 72 hours |
| | NOEC | Green algae (Selenastrum capricornutum) | 530 mg/l, 72 hours |
| Crustacea | EC50 | Water flea (Daphnia magna) | > 2300 mg/l, 48 hours Static test |
| | NOEC | Water flea (Daphnia magna) | 2300 mg/l, 48 hours Static test |
| Fish | EC50 | Bluegill sunfish (Adult Lepomis macrochirus) | > 930 mg/l, 96 hours Static test |
| | | Rainbow trout (Adult Oncorhyncus mykiss) | > 1000 mg/l, 96 hours Static test |
| | NOEC | Bluegill sunfish (Adult Lepomis macrochirus) | 930 mg/l, 96 hours Static test |
| | | Rainbow trout (Adult Oncorhyncus mykiss) | 1000 mg/l, 96 hours Static test |
| MAGNESIUM STEARATE | (CAS 557-04-0) | | |
| Aquatic | | | |
| Acute | | | |
| Fish | EC50 | Orange-red killfish (Adult Oryzias latipes) | 130 mg/l, 96 hours |
| Microtox | EC50 | Microtox | 12.5 mg/l, 15 minutes |

2928 Version No.: 20 Revision date: 11-July-2014 Issue date: 11-July-2014

Components Species Test results

| Components | | Species | Test results |
|--------------------------------|----------------|--|------------------------------------|
| POTASSIUM CLAVULANATE | (CAS 61177-45- | 5) | |
| Aquatic | | | |
| Acute | | | |
| Algae | EC50 | Green algae (Selenastrum capricornutum) | 56 mg/l, 72 hours |
| | NOEC | Green algae (Selenastrum capricornutum) | 9.4 mg/l, 72 hours |
| Crustacea | EC50 | Water flea (Daphnia magna) | 1610 mg/l, 48 hours Static test |
| | NOEC | Water flea (Daphnia magna) | 530 mg/l, 48 hours Static test |
| Fish | EC50 | Bluegill sunfish (Adult Lepomis macrochirus) | > 790 mg/l, 96 hours Static test |
| | | Rainbow trout (Adult Oncorhyncus mykiss) | > 960 mg/l, 96 hours Static test |
| | NOEC | Bluegill sunfish (Adult Lepomis macrochirus) | 790 mg/l, 96 hours Static test |
| | | Rainbow trout (Adult Oncorhyncus mykiss) | 960 mg/l, 96 hours Static test |
| Silicon dioxide (CAS 7631-86-9 | 9) | | |
| Aquatic | | | |
| Acute | | | |
| Algae | EC50 | Green algae (Selenastrum capricornutum) | 440 mg/l, 72 hours |
| | NOEC | Green algae (Selenastrum capricornutum) | 60 mg/l, 72 hours |
| Crustacea | EC50 | Water flea (Daphnia magna) | > 10000 mg/l, 24 hours Static test |
| Fish | EC50 | Common carp (Juvenile Cyprinus carpio) | > 10000 mg/l, 72 hours |
| | | Zebra fish (Adult Brachydanio rerio) | 5000 mg/l, 96 hours Static test |
| | | | |

^{*} Estimates for product may be based on additional component data not shown.

EC50

12.2. Persistence and degradability

Microtox

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

Microtox

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Hydrolysis

Half-life (Hydrolysis-acidic)

POTASSIUM CLAVULANATE 11.9 Hours Measured

Half-life (Hydrolysis-basic)

POTASSIUM CLAVULANATE 9.92 Hours Measured

Half-life (Hydrolysis-neutral)

AMOXICILLIN TRIHYDRATE 50 - 113 Days Measured POTASSIUM CLAVULANATE 28.3 Hours Measured

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

AMOXICILLIN TRIHYDRATE 88 %, 28 days Zahn-Wellens, Activated sludge

MAGNESIUM STEARATE 77 %, 28 days BOD

POTASSIUM CLAVULANATE 90 %, 28 days Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

AMOXICILLIN TRIHYDRATE -1.56

POTASSIUM CLAVULANATE -5.8 (Estimated).

8700 mg/l, 15 minutes

Bioconcentration factor (BCF)

> 9999 Estimated MAGNESIUM STEARATE

12.4. Mobility in soil

Adsorption

Sludge/biomass distribution coefficient - log Kd

AMOXICILLIN TRIHYDRATE -0.17 Estimated

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5.86 Estimated

Mobility in general

Volatility

Henry's law

AMOXICILLIN TRIHYDRATE 0 atm m³/mol Calculated

12.5. Results of PBT

Not available.

and vPvB assessment

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Empty containers should be taken to an approved waste handling site for recycling or disposal. Contaminated packaging

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Dispose in Disposal methods/information

accordance with all applicable regulations.

Special precautions Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Material name: AUGMENTIN TABLETS SDS LIK

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at

work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations Young people under 18 years old are not allowed to work with this product according to the EU

Directive 94/33/EC on the protection of young people at work. Follow national regulation for work

with chemical agents.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations Not available.

References GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements

under Sections 2 to 15 R11 Highly flammable.

R17 Spontaneously flammable in air.

R42/43 May cause sensitization by inhalation and skin contact.

H228 Flammable solid.

H251 Self-heating: may catch fire. H317 May cause an allergic skin reaction.

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Revision information Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Ingredients

Physical & Chemical Properties:

Transport Information: Material Transportation Information

Regulatory Information: United States

HazReg Data: Transportation

GHS: Classification

Training information Follow training instructions when handling this material.

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Material name: AUGMENTIN TABLETS

2928 Version No.: 20 Revision date: 11-July-2014 Issue date: 11-July-2014 10 / 10